Granules India Limited has informed the Exchange regarding a press release dated Jun 03, 2026, titled "Granules Pharmaceuticals, Inc. Receives USFDA EIR for Chantilly Facility".
GRANULES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Granules India's wholly-owned US subsidiary, Granules Pharmaceuticals, Inc., has received an Establishment Inspection Report (EIR) from the USFDA for its Chantilly facility. An EIR is issued by the USFDA after it concludes an inspection of a drug manufacturing site, signalling that the inspection has been formally closed. Receiving an EIR without any 'Official Action Indicated' status effectively means the facility has satisfactorily met USFDA compliance expectations. The Chantilly facility is part of Granules India's US manufacturing and distribution operations serving the American pharmaceutical market. The company has shared this development through a press release dated June 3, 2026.
Positive for shareholders — the clean closure of the USFDA inspection removes any regulatory overhang on the Chantilly plant, supporting uninterrupted supplies to the US market and reinforcing the company's compliance track record. This is likely to be viewed favourably by the market.